MedTrace Logo

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

NCT03549832 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-03-19

No results posted yet for this study

Summary

Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/ paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to prior Sofosbuvir/ Daclatasvir regimens in an open-labeled randomized trial.

Conditions

  • HCV Coinfection

Interventions

DRUG

Sofosbuvir

Sofosbuvir 400 mg oral pills

DRUG

Simeprevir

Simeprevir 150 mg oral pills

DRUG

Daclatasvir

Daclatasvir 60 mg oral pills

DRUG

Ribavirin

Ribavirin 200 mg oral pills

DRUG

Ombitasvir/paritaprevir/ritonavir

Ombitasvir/paritaprevir/ritonavir oral pills

Sponsors & Collaborators

  • Sohag University

    collaborator OTHER

  • South Valley University

    collaborator OTHER

  • Assiut University

    lead OTHER

Principal Investigators

  • Mohamed Mekky, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-01-30
Completion
2019-01-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03549832 on ClinicalTrials.gov